MENU
BAX
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

BAX stock forecast, quote, news & analysis

Baxter offers a variety of medical supplies and equipment to providers... Show more

BAX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BAX with price predictions
Jun 12, 2026

BAX in upward trend: 10-day moving average moved above 50-day moving average on May 18, 2026

The 10-day moving average for BAX crossed bullishly above the 50-day moving average on May 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 13, 2026. You may want to consider a long position or call options on BAX as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BAX just turned positive on May 12, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

BAX moved above its 50-day moving average on May 18, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 170 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BAX broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.783) is normal, around the industry mean (4.438). P/E Ratio (87.846) is within average values for comparable stocks, (185.236). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (3.445). Dividend Yield (0.010) settles around the average of (0.024) among similar stocks. P/S Ratio (0.947) is also within normal values, averaging (65.784).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

A.I.Advisor
published Dividends

BAX is expected to pay dividends on July 01, 2026

Baxter International BAX Stock Dividends
A dividend of $0.01 per share will be paid with a record date of July 01, 2026, and an ex-dividend date of May 29, 2026. The last dividend of $0.01 was paid on April 01. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 7.69B. The market cap for tickers in the group ranges from 126 to 145.58B. ISRG holds the highest valuation in this group at 145.58B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was -15%. CUPR experienced the highest price growth at 63%, while GCTK experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 111%. For the same stocks of the Industry, the average monthly volume growth was 97% and the average quarterly volume growth was 127%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 66
Price Growth Rating: 58
SMR Rating: 84
Profit Risk Rating: 96
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
BAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices

Industry PharmaceuticalsOther

Profile
Details
Industry
Medical Specialties
Address
One Baxter Parkway
Phone
+1 224 948-2000
Employees
60000
Web
https://www.baxter.com
BAX in upward trend: 10-day moving average moved above 50-day moving average on May 18, 2026